Clinical trials: Cell Transplantation
Diffuse Large B-Cell Lymphoma
A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.
The purpose of this study is to learn about the effects of two study medicines (maplirpacept [PF-07901801] and glofitamab) when given together for the treatment of diffuse large B-cell lymphoma (DLBCL) that is relapsed or is…
- Trial name
- MAPtivate-6 (NCT05896163)
- Testing
- maplirpacept (PF-07901801), Glofitamab, Obinutuzumab
- Where
- 10 sites in United States, Israel and 2 more
- Volunteers
- 40 people
- Sponsor
- Pfizer
Cervical Spinal Cord Injury, Spine Injury
Dose Escalation Study of AST-OPC1 in Spinal Cord Injury
The purpose of this study is to evaluate the safety of cross sequential escalating doses of AST-OPC1 administered among 5 cohorts at a single time-point between 21 and 42 days post injury, inclusively, to subjects with subacute…
- Conditions
- Cervical Spinal Cord Injury, Spine Injury, Spinal Cord Trauma
- Trial name
- NCT02302157
- Testing
- AST-OPC1
- Where
- 9 sites in United States
- Volunteers
- 25 people
- Sponsor
- Lineage Cell Therapeutics, Inc.
Stomatitis
Recombinant Human Keratinocyte Growth Factor to Reduce Oral Mucositis in Hematologic Malignancy Patients Undergoing Peripheral Blood Stem Cell Transplantation After Radiation and High-dose Chemotherapy
Radiotherapy and high dose chemotherapy with bone marrow transplantation or peripheral blood stem cell transplantation is frequently used as treatment for patients with cancers of the bone marrow or lymph nodes such as Hodgkin's…
- Trial name
- NCT00041665
- Testing
- Recombinant Human Keratinocyte Growth Factor
- Sponsor
- Amgen
Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation
A Study Evaluating the Efficacy and Safety of Neihulizumab vs "Conventional Treatment" to Treat Sr-aGvHD
This study is to assess the efficacy of Neihulizumab versus "conventional therapy" and to evaluate safety, pharmacokinetics and immunogenicity in treating steroid-refractory acute Graft-vs-Host Disease
- Trial name
- NCT02694770
- Testing
- Neihulizumab Treatment, Conventional Treatment
- Where
- 2 sites in United States
- Sponsor
- AbGenomics B.V Taiwan Branch
Multiple Myeloma
Safety and Efficacy Study of High Dose Melphalan to Treat Multiple Myeloma
The purpose of the study is to evaluate the safety and effectiveness of melphalan for injection for autologous stem cell transplant in multiple myeloma
- Trial name
- MM (NCT01572688)
- Testing
- Melphalan
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shandong Lanjin Pharmaceuticals Co.,Ltd
E Coli Infections, Allogenic Transplant Patients
Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant
This is a Phase 1b/2a study in allogenic hematopoietic stem cell transplant patients to investigate the safety, PK, PD and preliminary efficacy of multiple oral administrations of SNIPR001 when given concomitantly with SoC…
- Trial name
- NCT06938867
- Testing
- SNIPR001 consists of genetically modified bacteriophages specifically targeting Escherichia coli
- Where
- 10 sites in United States
- Volunteers
- 66 people
- Sponsor
- SNIPR Biome Aps.
Graft Versus Host Disease
Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)
The clinical trial is a Phase 1/2a, open-label, multi-center, dose-escalation study to evaluate the safety, tolerability and pharmacokinetic profile of RGI-2001 in patients undergoing AHSCT, with radiation or non-radiation…
- Trial name
- NCT01379209
- Testing
- RGI-2001, Calcineurin Inhibitors, Allogeneic Hematopoietic Stem Cell Transplantation
- Where
- 6 sites in United States
- Volunteers
- 68 people
- Sponsor
- Regimmune Corporation
Cytomegalovirus Infection
Maribavir for Prevention of CMV After Stem Cell Transplants
Cytomegalovirus (CMV) infections remain a significant problem following various types of transplants that are associated with strong immunosuppressive therapy.
- Trial name
- NCT00223925
- Testing
- Maribavir
- Where
- 13 sites in United States
- Volunteers
- 111 people
- Sponsor
- Shire
Merkel Cell Carcinoma, Basal Cell Carcinoma
Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies
The purpose of this study is to assess the safety and efficacy of RP1 (administered into the tumor) in 90 patients who have received an organ transplant in the past and currently have skin cancer.
- Conditions
- Merkel Cell Carcinoma, Basal Cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Cancer
- Trial name
- ARTACUS (NCT04349436)
- Testing
- RP1, intra-tumoral injection, oncolytic virus
- Where
- 24 sites in United States
- Volunteers
- 69 people
- Sponsor
- Replimune, Inc.
Acute Myeloid Leukemia, Myelodysplasia
Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and Myelodysplasia-Excess Blasts (MDS-EB)
This research study is designed to selectively deplete CD117-positive cells from participants with AML and MDS-EB.
- Trial name
- NCT05223699
- Testing
- MGTA-117
- Where
- 8 sites in United States
- Volunteers
- 22 people
- Sponsor
- Magenta Therapeutics, Inc.
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukaemias (AML)
Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies
The primary goal of this study is to evaluate an alternative myeloablative, but reduced toxicity conditioning regimen in children, to describe the safety and efficacy of intravenous (i.v.) Treosulfan administered as part of a…
- Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukaemias (AML), Myelodysplastic Syndromes (MDS), Juvenile Myelomonocytic Leukaemias (JMML)
- Trial name
- NCT02333058
- Testing
- Treosulfan
- Where
- 24 sites in Austria, Czechia and 4 more
- Volunteers
- 70 people
- Sponsor
- medac GmbH
Osteoarthritis
Safety and Efficacy of Autologous Bone Marrow Stem Cells for Treating Osteoarthritis
Osteoarthritis is a leading cause of chronic disability in elderly and the risk of disability attributed to osteoarthritis is as great as or greater than due to any other medical condition in that age group.
- Trial name
- NCT01152125
- Testing
- Autologous bone marrow stem cells
- Where
- India
- Volunteers
- 10 people
- Sponsor
- International Stemcell Services Limited
Acute Myocardial Infarction
EXCELLENT (EXpanded CELL ENdocardiac Transplantation)
A multicentric controlled phase I / IIb study evaluating the safety and the efficacy of in vitro expanded peripheral blood CD34+ stem cells output by the StemXpand® Automated Process, and injected in patients with an acute…
- Trial name
- EXCELLENT (NCT02669810)
- Testing
- PROTHERACYTES, Standard Treatment for CHF post AMI
- Where
- 13 sites in France, United Kingdom
- Volunteers
- 49 people
- Sponsor
- CellProthera
Graft-versus-host Disease, Acute-graft-versus-host Disease
An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)
This is a study comparing the defibrotide prophylaxis arm vs standard of care arm for the prevention of aGvHD.
- Trial name
- NCT03339297
- Testing
- Defibrotide, Standard of Care
- Where
- 62 sites in United States, Austria and 12 more
- Volunteers
- 152 people
- Sponsor
- Jazz Pharmaceuticals
Graft vs Host Disease
Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant
This open-label, single-arm, Phase II multi-center study enrolled 46 participants and investigated the activity, pharmacokinetics and safety of ruxolitinib added to the subject's immunosuppressive regimen among infants, children…
- Trial name
- REACH 5 (NCT03774082)
- Testing
- INC424
- Where
- 21 sites in Brazil, Canada and 12 more
- Volunteers
- 46 people
- Sponsor
- Novartis Pharmaceuticals
Relapse Multiple Myeloma, Multiple Myeloma
A Study of OPD5 Followed by Autologous Stem Cell Transplant for Patients With Relapsed Refractory Multiple Myeloma
The purpose of this study is to evaluate the safety and tolerability of a single infusion of OPD5 before Autologous Stem Cell Transplant in patients with RRMM.
- Trial name
- COAST (NCT04918511)
- Testing
- OPD5
- Where
- 3 sites in Czechia
- Sponsor
- Oncopeptides AB
Beta-Thalassemia Major, Sickle Cell Disease
A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in β-Thalassemia Major (Also Referred to as Transfusion-dependent β-Thalassemia [TDT]) and Sickle Cell Disease
This is a Phase 1/2, open label, safety, and efficacy study of the administration of LentiGlobin BB305 Drug Product to participants with either transfusion dependent beta-thalassemia (TDT) or sickle cell disease (SCD).
- Trial name
- NCT02151526
- Testing
- LentiGlobin BB305 Drug Product
- Where
- France
- Volunteers
- 7 people
- Sponsor
- Genetix Biotherapeutics Inc.
Multiple Myeloma
A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma Patients
The purpose of this study is to determine whether doxorubicin HCL liposome injection, bortezomib, and Dexamethasone in combination, are effective in previously untreated multiple myeloma patients.
- Trial name
- NCT00561743
- Testing
- Bortezomib + pegylated liposomal doxorubicin HCl + dexamethasone
- Volunteers
- 50 people
- Sponsor
- Janssen-Ortho Inc., Canada
Avascular Necrosis of the Femoral Head
Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Avascular Necrosis of the Femoral Head
The purpose of this study is to investigate the efficacy and safety of autologous transplantation of Adipose Tissue derived Mesenchymal stem cells (MSCs) in patient with avascular necrosis of the femoral head.
- Trial name
- NCT01643655
- Testing
- Autologous Adipose Tissue derived MSCs Transplantation
- Where
- South Korea
- Volunteers
- 15 people
- Sponsor
- R-Bio
Lymphoma, Hodgkin's Lymphoma
Pegfilgrastim PBPC Mobilization Study
This is a randomized, double-blind, multi-center study to assess the safety and effectiveness of using a single subcutaneous (under the skin) injection of pegfilgrastim or daily subcutaneous injections of Filgrastim to mobilize…
- Conditions
- Lymphoma, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Hematology
- Trial name
- NCT00066092
- Testing
- pegfilgrastim 12 mg, filgrastim, pegfilgrastim 6 mg
- Volunteers
- 41 people
- Sponsor
- Amgen